What is Psoriasis?
Psoriasis is an inflammatory skin condition that involves red elevated patches and flaking silvery scales. Psoriasis can be painful and itchy with dry, flaky, inflamed skin. It is most commonly found on the elbows, knees, scalp, chest, and lower back. It is thought to be caused by a malfunctioning immune system where white blood cells are triggered, causing inflammation and skin cells to shed at an abnormally quick rate.
- Topical corticosteroids
- Topical derivatives of vitamin D (calcitriol and calcipotriol)
- Topical derivatives of vitamin A (tazarotene)
- Coal tar
- Light therapy
- Biologics (alefacept, etanercept, adalimumab, infliximab, ustekinumab)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Age 18 years and over
- Moderate to severe chronic plaque psoriasis
- 52 weeks of treatment with Bimekizumab injections, Ustekinumab injections, or placebo injections. Subjects in placebo group will receive Bimekizumab after 16 weeks. Possible open-label extension after the initial 52 weeks.
- Approximately 17 clinic visits over a period of about 56 weeks plus possible open-label long-term extension.
Sponsor: BOND AVILLION
A phase 2b randomized, double-blind, placebo-controlled, multicenter 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with moderate to severe chronic plaque-type psoriasis
- Age 18 to 75 years
- Moderate to severe psoriasis
- 12 weeks of M1095 injections, Secukinumab injections, or placebo injections, followed by 32 weeks of M1095 or Secukinumab injections with a possible dose hold period depending on response
- Approximately 21 clinic visits over a period of about 56 weeks